白细胞介素4治疗银屑病：多效性细胞因子是否适合用于自身免疫性疾病的治疗？

Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases?

作者信息

Martin Roland

机构信息

Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center DR MSC 1400, Bethesda, MD 20892-1400, USA.

出版信息

Trends Pharmacol Sci. 2003 Dec;24(12):613-6. doi: 10.1016/j.tips.2003.10.006.

DOI:10.1016/j.tips.2003.10.006

PMID:14654299

Abstract

Many human autoimmune diseases are still treated by a combination of corticosteroids and general immunosuppression. A better understanding of the pathogenesis of these diseases has led to therapies that are more specific than current therapies of some of these disorders. In psoriasis, T helper (Th) cells with a pro-inflammatory phenotype (Th1) are considered essential to the disease process. A recent clinical trial of interleukin 4 in psoriasis has demonstrated that such pleiotropic cytokines can be used safely and effectively to correct imbalances in immune function.

摘要

许多人类自身免疫性疾病仍通过皮质类固醇和全身免疫抑制联合治疗。对这些疾病发病机制的深入了解催生了比目前某些此类疾病治疗方法更具特异性的疗法。在银屑病中，具有促炎表型的辅助性T（Th）细胞（Th1）被认为是疾病进程的关键因素。最近一项关于白细胞介素4治疗银屑病的临床试验表明，这类多效性细胞因子可安全有效地用于纠正免疫功能失衡。